stroke

[Journal of Cellular and Molecular Medicine] Human amniotic fluid stem cells could enhance cerebral vascular remodelling and have the potential to improve neurological function after stroke in diabetic rats.

[Experimental Neurology] Researchers investigated whether hypoxic postconditioning (HPC) could promote neurogenesis after ischemic stroke, and to investigate the role of neuronal stem cell metabolism in HPC-induced neuroprotection.

[nan] PathMaker Neurosystems, Inc. announced that it was awarded a Phase I STTR grant from NIH’s National Institute of Neurological Disorders and Stroke. The $371,000 award will enable the completion of key pre-clinical studies evaluating the effect of treatment with PathMaker’s breakthrough technology for motor neuron hyperexcitability suppression in transgenic ALS mice.

[Cell Reports] Investigators reported that AIM protein reduced sterile inflammation by attenuating damage-associated molecular patterns and that AIM administration ameliorated the deleterious effects of ischemic stroke.

[GNT Pharma Inc. (BusinessWire, Inc.)] GNT Pharma Inc. reported that the Korea Ministry of Food and Drug Safety has approved the Investigational New Drug Application for a phase III study of nelonemdaz for acute ischemic stroke patients.

[Global Blood Therapeutics, Inc.] Global Blood Therapeutics, Inc. announced that the US FDA has accepted for filing and review the company’s supplemental New Drug Application seeking accelerated approval for Oxbryta® for the treatment of sickle cell disease in children ages 4 to 11 years and its New Drug Application seeking approval for a new age-appropriate dispersible tablet dosage form of Oxbryta suitable for pediatric patients.